glp-1 semaglutide compound Troubling Findings in Study of Compounders Semaglutide Injection | Starts at

They [the findings] suggest that this drug class, typically used for managing diabetes and obesity, may serve as a dual-purpose treatment for patients with RA, addressing both systemic inflammation and associated comorbidities, such as cardiovascular disease, which is especially prevalent in patients with RAO and remains the leading cause of death in patients with RA overall, they said

An alcohol extraction helps pull these out

GI tolerability varies meaningfully across the class

Novo has developed a strong lead with UBSs forecasts projecting 400k total prescriptions at the end of Q1, with the majority of sales coming through cash-pay channels capturing net-new GLP-1 users